Filing Flows › Comparisons › APMD vs STOK
Apnimed vs Stoke Therapeutics: APMD and STOK compared
Apnimed is the larger company: $12.1M of revenue in its latest quarter (Q2 2026) against $11.3M for Stoke Therapeutics (Q3 2026). Stoke Therapeutics is growing faster (+6% against -29% a year earlier). Apnimed is more profitable, with an operating margin of -96.9% against -686.9%.
Where the money goes: APMD and STOK
Apnimed (APMD) · Q2 2026
Apnimed, Q2 2026: revenue $12.1M (-29% year over year), operating margin -96.9%, net earnings $126M. The chart follows the revenue to costs, profit and cash.
Stoke Therapeutics (STOK) · Q3 2026
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
| Apnimed (APMD) | Stoke Therapeutics (STOK) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $12.1M | $11.3M |
| Revenue growth, Y/Y | -29% | +6% |
| Operating margin | -96.9% | -686.9% |
| Net earnings | $126M | −$73.6M |
| Net margin | — | -654.3% |
| Operating cash flow | — | −$62.7M |
Questions
Which is bigger, Apnimed or Stoke Therapeutics?
Apnimed is the larger company: $12.1M of revenue in its latest quarter (Q2 2026) against $11.3M for Stoke Therapeutics (Q3 2026).
Is Apnimed or Stoke Therapeutics growing faster?
Stoke Therapeutics is growing faster (+6% against -29% a year earlier).
Which is more profitable, Apnimed or Stoke Therapeutics?
Apnimed is more profitable, with an operating margin of -96.9% against -686.9%.
More: Apnimed earnings · how Apnimed makes money · Stoke Therapeutics earnings · how Stoke Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Sep 8, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.